Inquiry

Left-sided Colitis Research Services

Left-sided ulcerative colitis is not a separate entity but a less severe form of pancolitis. In left-sided colitis, the inflammation occurs only on the left side of the colon. It's also called distal ulcerative colitis (UC). Left-sided colitis can cause loss of appetite, weight loss, pain in the left side of your abdomen, or bloody diarrhea. It's not clear why UC works this way. It could be genetic, or immune-mediated, or related to gut bacteria, or the blood supply to the gut, or something else. The primary treatment for left-sided disease is topical 5-aminosalicyclic acid (5-ASA) agents.

Customized Studies for Left-sided Colitis

Ace Therapeutics is at the forefront of preclinical research in left-sided colitis, focusing on utilizing reliable animal models of IBD to help clients understand the complex mechanisms of left-sided colitis and accelerate the development of your therapies. Our ability to provide multi-faceted outcome studies means that you will have the data that best fits your drug discovery program.

Drug Development Services for Left-sided Colitis

With the expertise and extensive experience of our team of experts in the field of left-sided colitis, Ace Therapeutics helps pharmaceutical and biotechnology companies develop drugs for left sided colitis. We are able to provide our clients with greater agility and flexibility, allowing us to accelerate the time it takes to bring drugs to market.

• Target discovery and screening. We help clients study the pathogenesis of left-sided colitis and identify new therapeutic targets. Potential candidate compounds are discovered through computer-aided drug design, high-throughput screening, and other methods.
• Lead compound optimization. Our experts conduct structure-activity relationship studies on candidate compounds to optimize their efficacy, pharmacokinetics, safety, etc.
• In vitro and animal studies. We offer in vitro studies based on intestinal epithelial cells to validate compound activity and mechanism of action. We also provide reliable animal models of ulcerative colitis to evaluate the efficacy of drugs for the treatment of left-sided colitis.
• Preclinical DMPK. We offer a comprehensive range of services including in vitro ADME, toxicity (in vitro ADMET) and in vivo pharmacokinetic (PK) for rapid assessment of the DMPK properties and toxicity of compounds.

Type of Drugs We Can Develop for Left-sided Colitis

• Corticosteroids
• Immunosuppressants
• Biologics
• JAK inhibitors

At Ace Therapeutics, collaboration is critical to advancing preclinical studies in left-sided colitis. By building strong partnerships, we strive to enhance your understanding of this disease and develop effective strategies to support your research. Contact us to accelerate your next breakthrough.